TNFα- and IL-17A-mediated S100A8 expression is regulated by p38 MAPK

Novel insights into the role of S100A8/A9 in skin biology

(2012) Claus Kerkhoff et al.   EXPERIMENTAL DERMATOLOGY

Tumor Necrosis Factor α-Mediated Induction of Interleukin 17C in Human Keratinocytes Is Controlled by Nuclear Factor κB

(2011) Claus Johansen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy

(2010) C. Johansen et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement

(2010) L. Soegaard-Madsen et al.   BRITISH JOURNAL OF DERMATOLOGY

Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions

(2010) P. ETTEHADI et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The role of mitogen- and stress-activated protein kinase 1 and 2 in chronic skin inflammation in mice

(2010) Trine Bertelsen et al.   EXPERIMENTAL DERMATOLOGY

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis

(2010) Andrea Chiricozzi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells

(2010) Karin Loser et al.   NATURE MEDICINE

Changes in S100A8 expression in UV-irradiated and aged human skin in vivo

(2009) Young Mee Lee et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review

(2007) Daniel Tracey et al.   PHARMACOLOGY & THERAPEUTICS